Related Experiment Video
Updated: Jun 24, 2026
08:49
Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
Published on: August 2, 2024
Features of cardiac allograft coronary endothelial dysfunction
Eugenia Raichlin1, Sudhir S Kushwaha, Ryan J Lennon
1Mayo Clinic, Rochester, Minnesota, USA.
The American Journal of Cardiology
|April 14, 2009
Summary
Heart transplant recipients show abnormal epicardial coronary endothelial function, potentially due to impaired nitric oxide production. This impacts cardiac allograft health and requires further investigation for improved patient outcomes.
Area of Science:
- Cardiology
- Transplantation Immunology
- Vascular Biology
Background:
- Cardiac allograft vasculopathy is a major cause of long-term graft loss.
- Endothelial dysfunction plays a critical role in the development of cardiac allograft vasculopathy.
- The specific mechanisms of endothelial dysfunction in cardiac allografts remain incompletely understood.
Purpose of the Study:
- To evaluate the features and mechanism of cardiac allograft coronary endothelial dysfunction.
- To compare endothelial function between heart transplant recipients and healthy controls.
Main Methods:
- Assessed coronary blood flow and epicardial coronary artery diameter responses to acetylcholine and N(G)-monomethyl-l-arginine in 19 heart transplant recipients and 19 controls.
- Utilized intracoronary infusions and measured coronary artery diameter and blood flow.
- Coronary angiograms were normal in all participants.
Main Results:
- Heart transplant recipients exhibited greater epicardial vasoconstriction to acetylcholine (p=0.036).
- Microvascular endothelial function was similar between groups.
- The response to N(G)-monomethyl-l-arginine was attenuated in transplant recipients, suggesting impaired nitric oxide synthesis (p=0.018 for blood flow).
Conclusions:
- Cardiac allograft epicardial coronary endothelial function is abnormal in heart transplant recipients.
- Impaired endothelial nitric oxide production, possibly due to an impaired endogenous NO synthetase pathway, contributes to this dysfunction.
- These findings highlight a potential therapeutic target for preventing cardiac allograft vasculopathy.
